Migrating a lab-developed MERS-CoV real-time PCR to 3 “Sample to Result” systems: experiences on optimization and validation
Identifieur interne : 000C05 ( Pmc/Corpus ); précédent : 000C04; suivant : 000C06Migrating a lab-developed MERS-CoV real-time PCR to 3 “Sample to Result” systems: experiences on optimization and validation
Auteurs : Glynis Frans ; Kurt Beuselinck ; Bart Peeters ; Marc Van Ranst ; Veroniek Saegeman ; Stefanie Desmet ; Katrien LagrouSource :
- Diagnostic Microbiology and Infectious Disease [ 0732-8893 ] ; 2019.
Abstract
The goal of the study was to adapt our Middle East respiratory syndrome coronavirus (MERS-CoV) lab-developed test (LDT) to 3 “Sample to Result” (S2R) systems: BD MAX (BD), ELITe InGenius (ELITechGroup), and ARIES (Luminex).
The BD MAX and InGenius system allowed use of lab-developed primers and TaqMan probes, while ARIES required conversion to MultiCode primers for melting curve analysis. Each device required ≤1 day of training and assay optimization. No discordant results were noted after analysis of 32 External Quality Control (EQC) samples. On a 10-fold dilution series of a MERS-CoV–positive EQC sample, InGenius obtained the highest detection rate. Laboratory technicians rated the ARIES as the user-friendliest. It also required the least hands-on time. BD MAX had the lowest turnaround time and highest throughput.
While each device had distinguishing system properties with associated (dis)advantages, the 3 S2R systems were comparable in terms of assay development and validation.
Url:
DOI: 10.1016/j.diagmicrobio.2019.02.006
PubMed: 30929995
PubMed Central: 7127711
Links to Exploration step
PMC:7127711Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Migrating a lab-developed MERS-CoV real-time PCR to 3 “Sample to Result” systems: experiences on optimization and validation</title><author><name sortKey="Frans, Glynis" sort="Frans, Glynis" uniqKey="Frans G" first="Glynis" last="Frans">Glynis Frans</name></author><author><name sortKey="Beuselinck, Kurt" sort="Beuselinck, Kurt" uniqKey="Beuselinck K" first="Kurt" last="Beuselinck">Kurt Beuselinck</name></author><author><name sortKey="Peeters, Bart" sort="Peeters, Bart" uniqKey="Peeters B" first="Bart" last="Peeters">Bart Peeters</name></author><author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name></author><author><name sortKey="Saegeman, Veroniek" sort="Saegeman, Veroniek" uniqKey="Saegeman V" first="Veroniek" last="Saegeman">Veroniek Saegeman</name></author><author><name sortKey="Desmet, Stefanie" sort="Desmet, Stefanie" uniqKey="Desmet S" first="Stefanie" last="Desmet">Stefanie Desmet</name></author><author><name sortKey="Lagrou, Katrien" sort="Lagrou, Katrien" uniqKey="Lagrou K" first="Katrien" last="Lagrou">Katrien Lagrou</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">30929995</idno><idno type="pmc">7127711</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127711</idno><idno type="RBID">PMC:7127711</idno><idno type="doi">10.1016/j.diagmicrobio.2019.02.006</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000C05</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000C05</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Migrating a lab-developed MERS-CoV real-time PCR to 3 “Sample to Result” systems: experiences on optimization and validation</title><author><name sortKey="Frans, Glynis" sort="Frans, Glynis" uniqKey="Frans G" first="Glynis" last="Frans">Glynis Frans</name></author><author><name sortKey="Beuselinck, Kurt" sort="Beuselinck, Kurt" uniqKey="Beuselinck K" first="Kurt" last="Beuselinck">Kurt Beuselinck</name></author><author><name sortKey="Peeters, Bart" sort="Peeters, Bart" uniqKey="Peeters B" first="Bart" last="Peeters">Bart Peeters</name></author><author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name></author><author><name sortKey="Saegeman, Veroniek" sort="Saegeman, Veroniek" uniqKey="Saegeman V" first="Veroniek" last="Saegeman">Veroniek Saegeman</name></author><author><name sortKey="Desmet, Stefanie" sort="Desmet, Stefanie" uniqKey="Desmet S" first="Stefanie" last="Desmet">Stefanie Desmet</name></author><author><name sortKey="Lagrou, Katrien" sort="Lagrou, Katrien" uniqKey="Lagrou K" first="Katrien" last="Lagrou">Katrien Lagrou</name></author></analytic><series><title level="j">Diagnostic Microbiology and Infectious Disease</title><idno type="ISSN">0732-8893</idno><idno type="eISSN">1879-0070</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The goal of the study was to adapt our Middle East respiratory syndrome coronavirus (MERS-CoV) lab-developed test (LDT) to 3 “Sample to Result” (S2R) systems: BD MAX (BD), ELITe InGenius (ELITechGroup), and ARIES (Luminex).</p><p>The BD MAX and InGenius system allowed use of lab-developed primers and TaqMan probes, while ARIES required conversion to MultiCode primers for melting curve analysis. Each device required ≤1 day of training and assay optimization. No discordant results were noted after analysis of 32 External Quality Control (EQC) samples. On a 10-fold dilution series of a MERS-CoV–positive EQC sample, InGenius obtained the highest detection rate. Laboratory technicians rated the ARIES as the user-friendliest. It also required the least hands-on time. BD MAX had the lowest turnaround time and highest throughput.</p><p>While each device had distinguishing system properties with associated (dis)advantages, the 3 S2R systems were comparable in terms of assay development and validation.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Azhar, E I" uniqKey="Azhar E">E.I. Azhar</name></author><author><name sortKey="El Kafrawy, S A" uniqKey="El Kafrawy S">S.A. El-Kafrawy</name></author><author><name sortKey="Farraj, S A" uniqKey="Farraj S">S.A. Farraj</name></author><author><name sortKey="Hassan, A M" uniqKey="Hassan A">A.M. Hassan</name></author><author><name sortKey="Al Saeed, M S" uniqKey="Al Saeed M">M.S. Al-Saeed</name></author><author><name sortKey="Hashem, A M" uniqKey="Hashem A">A.M. Hashem</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Beal, S G" uniqKey="Beal S">S.G. Beal</name></author><author><name sortKey="Assarzadegan, N" uniqKey="Assarzadegan N">N. Assarzadegan</name></author><author><name sortKey="Rand, K H" uniqKey="Rand K">K.H. Rand</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Boheemen, S" uniqKey="Van Boheemen S">S. van Boheemen</name></author><author><name sortKey="De Graag, M" uniqKey="De Graag M">M. de Graag</name></author><author><name sortKey="Lauber, C" uniqKey="Lauber C">C. Lauber</name></author><author><name sortKey="Bestebroer, T M" uniqKey="Bestebroer T">T.M. Bestebroer</name></author><author><name sortKey="Raj, V S" uniqKey="Raj V">V.S. Raj</name></author><author><name sortKey="Zaki, A M" uniqKey="Zaki A">A.M. Zaki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Clancy, A" uniqKey="Clancy A">A. Clancy</name></author><author><name sortKey="Crowley, B" uniqKey="Crowley B">B. Crowley</name></author><author><name sortKey="Niesters, H" uniqKey="Niesters H">H. Niesters</name></author><author><name sortKey="Herra, C" uniqKey="Herra C">C. Herra</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Corman, V M" uniqKey="Corman V">V.M. Corman</name></author><author><name sortKey="Eckerle, I" uniqKey="Eckerle I">I. Eckerle</name></author><author><name sortKey="Bleicker, T" uniqKey="Bleicker T">T. Bleicker</name></author><author><name sortKey="Zaki, A" uniqKey="Zaki A">A. Zaki</name></author><author><name sortKey="Landt, O" uniqKey="Landt O">O. Landt</name></author><author><name sortKey="Eschbach Bludau, M" uniqKey="Eschbach Bludau M">M. Eschbach-Bludau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Felder, R A" uniqKey="Felder R">R.A. Felder</name></author><author><name sortKey="Jackson, K D" uniqKey="Jackson K">K.D. Jackson</name></author><author><name sortKey="Walter, A M" uniqKey="Walter A">A.M. Walter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Groot, R J" uniqKey="De Groot R">R.J. de Groot</name></author><author><name sortKey="Baker, S C" uniqKey="Baker S">S.C. Baker</name></author><author><name sortKey="Baric, R S" uniqKey="Baric R">R.S. Baric</name></author><author><name sortKey="Brown, C S" uniqKey="Brown C">C.S. Brown</name></author><author><name sortKey="Drosten, C" uniqKey="Drosten C">C. Drosten</name></author><author><name sortKey="Enjuanes, L" uniqKey="Enjuanes L">L. Enjuanes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Johnson, S C" uniqKey="Johnson S">S.C. Johnson</name></author><author><name sortKey="Sherrill, C B" uniqKey="Sherrill C">C.B. Sherrill</name></author><author><name sortKey="Marshall, D J" uniqKey="Marshall D">D.J. Marshall</name></author><author><name sortKey="Moser, M J" uniqKey="Moser M">M.J. Moser</name></author><author><name sortKey="Prudent, J R" uniqKey="Prudent J">J.R. Prudent</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Juretschko, S" uniqKey="Juretschko S">S. Juretschko</name></author><author><name sortKey="Mahony, J" uniqKey="Mahony J">J. Mahony</name></author><author><name sortKey="Buller, R S" uniqKey="Buller R">R.S. Buller</name></author><author><name sortKey="Manji, R" uniqKey="Manji R">R. Manji</name></author><author><name sortKey="Dunbar, S" uniqKey="Dunbar S">S. Dunbar</name></author><author><name sortKey="Walker, K" uniqKey="Walker K">K. Walker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lu, X" uniqKey="Lu X">X. Lu</name></author><author><name sortKey="Whitaker, B" uniqKey="Whitaker B">B. Whitaker</name></author><author><name sortKey="Sakthivel, S K" uniqKey="Sakthivel S">S.K. Sakthivel</name></author><author><name sortKey="Kamili, S" uniqKey="Kamili S">S. Kamili</name></author><author><name sortKey="Rose, L E" uniqKey="Rose L">L.E. Rose</name></author><author><name sortKey="Lowe, L" uniqKey="Lowe L">L. Lowe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sherrill, C B" uniqKey="Sherrill C">C.B. Sherrill</name></author><author><name sortKey="Marshall, D J" uniqKey="Marshall D">D.J. Marshall</name></author><author><name sortKey="Moser, M J" uniqKey="Moser M">M.J. Moser</name></author><author><name sortKey="Larsen, C A" uniqKey="Larsen C">C.A. Larsen</name></author><author><name sortKey="Daude Snow, L" uniqKey="Daude Snow L">L. Daude-Snow</name></author><author><name sortKey="Jurczyk, S" uniqKey="Jurczyk S">S. Jurczyk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Voermans, J J" uniqKey="Voermans J">J.J. Voermans</name></author><author><name sortKey="Seven Deniz, S" uniqKey="Seven Deniz S">S. Seven-Deniz</name></author><author><name sortKey="Fraaij, P L" uniqKey="Fraaij P">P.L. Fraaij</name></author><author><name sortKey="Van Der Eijk, A A" uniqKey="Van Der Eijk A">A.A. van der Eijk</name></author><author><name sortKey="Koopmans, M P" uniqKey="Koopmans M">M.P. Koopmans</name></author><author><name sortKey="Pas, S D" uniqKey="Pas S">S.D. Pas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="World Health Organization Who" uniqKey="World Health Organization Who">World Health Organization (WHO)</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zaki, A M" uniqKey="Zaki A">A.M. Zaki</name></author><author><name sortKey="Van Boheemen, S" uniqKey="Van Boheemen S">S. van Boheemen</name></author><author><name sortKey="Bestebroer, T M" uniqKey="Bestebroer T">T.M. Bestebroer</name></author><author><name sortKey="Osterhaus, A D" uniqKey="Osterhaus A">A.D. Osterhaus</name></author><author><name sortKey="Fouchier, R A" uniqKey="Fouchier R">R.A. Fouchier</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Diagn Microbiol Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Diagn. Microbiol. Infect. Dis</journal-id><journal-title-group><journal-title>Diagnostic Microbiology and Infectious Disease</journal-title></journal-title-group><issn pub-type="ppub">0732-8893</issn><issn pub-type="epub">1879-0070</issn><publisher><publisher-name>Elsevier Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30929995</article-id><article-id pub-id-type="pmc">7127711</article-id><article-id pub-id-type="publisher-id">S0732-8893(18)30503-0</article-id><article-id pub-id-type="doi">10.1016/j.diagmicrobio.2019.02.006</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Migrating a lab-developed MERS-CoV real-time PCR to 3 “Sample to Result” systems: experiences on optimization and validation</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0005"><name><surname>Frans</surname><given-names>Glynis</given-names></name><email>glynis.frans@uzleuven.be</email></contrib><contrib contrib-type="author" id="au0010"><name><surname>Beuselinck</surname><given-names>Kurt</given-names></name><email>kurt.beuselinck@uzleuven.be</email><xref rid="cr0005" ref-type="corresp">⁎</xref></contrib><contrib contrib-type="author" id="au0015"><name><surname>Peeters</surname><given-names>Bart</given-names></name><email>bart.peeters@uza.be</email><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0020"><name><surname>Van Ranst</surname><given-names>Marc</given-names></name><email>marc.vanranst@uzleuven.be</email></contrib><contrib contrib-type="author" id="au0025"><name><surname>Saegeman</surname><given-names>Veroniek</given-names></name><email>veroniek.saegeman@uzleuven.be</email></contrib><contrib contrib-type="author" id="au0030"><name><surname>Desmet</surname><given-names>Stefanie</given-names></name><email>stefanie.desmet@uzleuven.be</email></contrib><contrib contrib-type="author" id="au0035"><name><surname>Lagrou</surname><given-names>Katrien</given-names></name><email>katrien.lagrou@uzleuven.be</email></contrib></contrib-group><aff id="af0005">Department of Laboratory Medicine, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium</aff><author-notes><corresp id="cr0005"><label>⁎</label>Corresponding author. Tel.: +32-16-34-79-31. <email>kurt.beuselinck@uzleuven.be</email></corresp><fn id="fn0005"><label>1</label><p id="np0050">Present address: Department of Laboratory Medicine, University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>10</day><month>2</month><year>2019</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><month>8</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>10</day><month>2</month><year>2019</year></pub-date><volume>94</volume><issue>4</issue><fpage>349</fpage><lpage>354</lpage><history><date date-type="received"><day>16</day><month>10</month><year>2018</year></date><date date-type="rev-recd"><day>1</day><month>2</month><year>2019</year></date><date date-type="accepted"><day>4</day><month>2</month><year>2019</year></date></history><permissions><copyright-statement>© 2019 Elsevier Inc. All rights reserved.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Elsevier Inc.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="ab0005"><p>The goal of the study was to adapt our Middle East respiratory syndrome coronavirus (MERS-CoV) lab-developed test (LDT) to 3 “Sample to Result” (S2R) systems: BD MAX (BD), ELITe InGenius (ELITechGroup), and ARIES (Luminex).</p><p>The BD MAX and InGenius system allowed use of lab-developed primers and TaqMan probes, while ARIES required conversion to MultiCode primers for melting curve analysis. Each device required ≤1 day of training and assay optimization. No discordant results were noted after analysis of 32 External Quality Control (EQC) samples. On a 10-fold dilution series of a MERS-CoV–positive EQC sample, InGenius obtained the highest detection rate. Laboratory technicians rated the ARIES as the user-friendliest. It also required the least hands-on time. BD MAX had the lowest turnaround time and highest throughput.</p><p>While each device had distinguishing system properties with associated (dis)advantages, the 3 S2R systems were comparable in terms of assay development and validation.</p></abstract><kwd-group id="ks0005"><title>Abbreviations</title><kwd>CoV, Coronaviruses</kwd><kwd>EQC, External Quality Control</kwd><kwd>LDT, Lab-developed test</kwd><kwd>MERS, Middle East respiratory syndrome</kwd><kwd>MERS-CoV, Middle East respiratory syndrome coronavirus</kwd><kwd>PDV, Phocine Distemper Virus</kwd><kwd>RT-PCR, Real-time reverse-transcription polymerase chain reaction</kwd><kwd>S2R, Sample to Result</kwd><kwd>SPC, Specimen Processing Control</kwd><kwd>UTM, Universal Transport Medium</kwd></kwd-group><kwd-group id="ks0010"><title>Keywords</title><kwd>Sample to result systems</kwd><kwd>Middle East respiratory syndrome coronavirus</kwd><kwd>BD MAX</kwd><kwd>ELITe InGenius</kwd><kwd>ARIES</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0005">In September 2012, a new Coronavirus (CoV) was identified in patients whom had traveled to or resided in Saudi Arabia and suffered from acute respiratory distress with acute kidney injury (<xref rid="bb0015" ref-type="bibr">van Boheemen et al., 2012</xref>, <xref rid="bb0070" ref-type="bibr">Zaki et al., 2012</xref>). Due to its geographic predilection, the novel CoV was named Middle East respiratory syndrome coronavirus (MERS-CoV) (<xref rid="bb0035" ref-type="bibr">de Groot et al., 2013</xref>, <xref rid="bb0015" ref-type="bibr">van Boheemen et al., 2012</xref>, <xref rid="bb0070" ref-type="bibr">Zaki et al., 2012</xref>). Although limited in number, patients have also been reported in North Africa, Europe, Asia, and North America after returning from the Arabian Peninsula or after having contact with infected individuals. MERS-CoV is defined as a zoonotic disease as it is transmitted to humans through dromedary camels. Human-to-human transmission is observed after close contact with infected patients (e.g., in healthcare settings) (<xref rid="bb0005" ref-type="bibr">Azhar et al., 2014</xref>).</p><p id="p0010">WHO criteria for a laboratory confirmed MERS-CoV infection require detection of viral nucleic acid or antibodies (acute and convalescent samples) (<xref rid="bb0065" ref-type="bibr">World Health Organization (WHO), 2015</xref>). For viral nucleic acid detection, diagnostic real-time reverse-transcription polymerase chain reaction (RT-PCR) assays were developed for qualitative and quantitative detection of MERS-CoV in lower respiratory tract specimens (highest sensitivity), upper respiratory tract specimens, and/or serum (<xref rid="bb0025" ref-type="bibr">Corman et al., 2012</xref>, <xref rid="bb0050" ref-type="bibr">Lu et al., 2014</xref>; <xref rid="bb0065" ref-type="bibr">World Health Organization (WHO), 2015</xref>). The ability to rapidly detect MERS-CoV in clinical specimens is important for the timely initiation of treatment and isolation measures (<xref rid="bb0005" ref-type="bibr">Azhar et al., 2014</xref>, <xref rid="bb0025" ref-type="bibr">Corman et al., 2012</xref>, <xref rid="bb0035" ref-type="bibr">de Groot et al., 2013</xref>, <xref rid="bb0050" ref-type="bibr">Lu et al., 2014</xref>, <xref rid="bb0015" ref-type="bibr">van Boheemen et al., 2012</xref>; <xref rid="bb0065" ref-type="bibr">World Health Organization (WHO), 2015</xref>; <xref rid="bb0070" ref-type="bibr">Zaki et al., 2012</xref>).</p><p id="p0015">“Sample to Result” (S2R) systems have revolutionized molecular diagnostics by automating nuclear extraction, amplification, and analysis inside 1 device (<xref rid="bb0010" ref-type="bibr">Beal et al., 2016</xref>). These systems provide fast results and can be operated in after-hour settings by laboratory technicians with limited molecular diagnostics experience (<xref rid="bb0010" ref-type="bibr">Beal et al., 2016</xref>). As the demand for urgent MERS-CoV PCR analyses increased in our center, especially after the yearly Hajj pilgrimage, we initiated this study to transfer our MERS-CoV lab-developed test (LDT) to an S2R system. Three devices were selected, evaluated, and compared in terms of hands-on experience, assay validation, and system properties.</p></sec><sec id="s0010"><label>2</label><title>Materials and methods</title><sec id="s0015"><label>2.1</label><title>MERS-CoV LDT</title><p id="p0020">Total nucleic acid (TNA) is extracted from nasopharyngeal swabs in Universal Transport Medium (UTM, COPAN, Brescia, Italy) using NucliSens extraction on easyMAG (BioMérieux, Lyon, France). Ten microliters of Phocine Distemper Virus (PDV) internal control (IC) (<xref rid="bb0020" ref-type="bibr">Clancy et al., 2008</xref>) (PDV stock kindly supplied by Groningen Medical Center, Groningen, The Netherlands) is added to 200 μL UTM sample to extract and elute 110 μL of TNA. Five microliters of TNA extract is mixed with 1× TaqMan Fast Virus 1-Step Master Mix (Thermo Fisher Scientific, Waltham, MA), 0.5 μM of each primer, and 0.2 μM of each probe in a total volume of 20 μL. The MERS-CoV Fast-PCR targets 3 genes using previously described primers and probes: MERS-CoV envelope gene <italic>UpE</italic> (<xref rid="bb0025" ref-type="bibr">Corman et al., 2012</xref>), MERS-CoV nucleocapsid gene <italic>N</italic> (<xref rid="bb0050" ref-type="bibr">Lu et al., 2014</xref>), and PDV hemagglutinin gene <italic>H</italic> (<xref rid="bb0020" ref-type="bibr">Clancy et al., 2008</xref>). Only the fluorescent dye combination for the MERS <italic>N</italic> gene probe was changed: Cy5-BHQ3. PCR amplification is performed on QuantStudio Dx (Thermo Fisher Scientific) using the following PCR temperature profile: 10 min 50 °C and 20 s 95 °C followed by 45 cycles of 3 s 95 °C and 30 s 60 °C. After the run, amplification plots are analyzed and interpreted using QuantStudio Test Development Software (version 1.0, Thermo Fisher Scientific). The presence of MERS-CoV in the sample is defined by amplification of <italic>UpE</italic> and/or <italic>N</italic> with the PDV IC.</p><p id="p0025">Specificity of our LDT on QuantStudio Dx was validated using External Quality Control (EQC) samples (MERS-CoV–positive versus –negative samples), high-titer cell cultures (positive for hCOV 229E, NL63, OC43, or SARS), and clinical samples (positive for hCoV 229E, NL63, OC43, or HKU-1). Our LDT proved specific for MERS-CoV, and no cross-reactions were detected.</p></sec><sec id="s0020"><label>2.2</label><title>S2R conversion and evaluation</title><p id="p0030">The assay was adapted to 3 S2R systems: BD MAX (<xref rid="bb0030" ref-type="bibr">Felder et al., 2014</xref>) (BD, Franklin Lakes, NJ), ELITe InGenius (ELITechGroup, Puteaux, France), and ARIES (<xref rid="bb0040" ref-type="bibr">Johnson et al., 2004</xref>, <xref rid="bb0045" ref-type="bibr">Juretschko et al., 2017</xref>, <xref rid="bb0055" ref-type="bibr">Sherrill et al., 2004</xref>) (Luminex, Austin, TX). A total of 200 μL of input sample volume was used for extraction, PCR amplification, and result interpretation. Whenever system properties allowed, 10 μL of the lab-developed PDV IC was added to the primary sample before extraction.</p><p id="p0035">Comparison and evaluation of the 3 devices were based on 3 elements; required extraction and PCR optimization, MERS-CoV assay validation, and hands-on system experience. Validation of the MERS-CoV assay included determination of accuracy, specificity, cross-contamination, and cross-reaction through analysis of 32 EQC samples (QCMD/Instand): 16 MERS-CoV positive, 8 OC43-CoV positive, 1 NL63-CoV positive, and 7 CoV negative. The detection rate was evaluated by analysis of 5 dilutions in a 10-fold dilution series of a strong positive MERS-CoV EQC sample (Ct value Quantstudio ≈ 22). UTM was used as the dilution buffer. Linearity and analysis efficiency (extraction + PCR) were calculated from the Ct values obtained on the 10-fold dilution series. Lab-developed goals for linearity and analysis efficiency were set at <italic>R</italic><sup>2</sup> > 0.950 and > 80%, respectively.</p><p id="p0040">The hands-on time was determined once by the same operator and was defined as the time required to perform the following steps on 4 different samples: sample preparation, device loading, and device clean-up. Based on the total analysis time (=hands-on + on-board extraction + PCR time) and device sample capacity, the maximum throughput in a 1-day shift of 7.5 h was calculated. Three laboratory technicians without experience in molecular diagnostics were asked to test and grade the ease of use of all devices with “Very easy,” “Easy,” “Moderate,” “Difficult,” or “Very difficult.” Results were combined if there were discordances (e.g., “Easy/moderate”). Any additional comments on the required training, device setup (including sample and reagent loading), software interface, quality of the generated report, and maintenance (including clean-up) were noted.</p></sec></sec><sec id="s0025"><label>3</label><title>Results</title><sec id="s0030"><label>3.1</label><title>Required extraction and PCR optimization</title><p id="p0045">The proposed sample input volume of 200 μl was used on each system (<xref rid="t0005" ref-type="table">Table 1</xref>). A volume of 10 μl in-house PDV IC was used as an extraction and amplification control on the BD MAX and InGenius. On ARIES, a Luminex-patented extraction and amplification control included in the reaction cassette was used (<xref rid="t0005" ref-type="table">Table 1</xref>).<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Required extraction/PCR optimization for the described MERS-CoV LDT.</p></caption><alt-text id="al0010">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th></th><th>ARIES</th><th>BD MAX</th><th>InGenius</th></tr></thead><tbody><tr><td>Required PCR optimization (time)</td><td>≤1 day</td><td>≤1 day</td><td>≤1 day</td></tr><tr><td>Sample volume (μL, range)</td><td>200 (200–400)</td><td>200 (100–750)</td><td>200 (200 or 1000<xref rid="tf0005" ref-type="table-fn">a</xref>)</td></tr><tr><td>Extract volume (μL, range)</td><td>150 (not applicable)</td><td>12.5 (not applicable)</td><td>50 (50, 100, or 200)</td></tr><tr><td>PCR reaction volume (μL, range)</td><td>56 (not applicable)</td><td>4 (not applicable)</td><td>20 (20 to 50)</td></tr><tr><td>Extract volume used for PCR (μL)</td><td>50</td><td>2</td><td>5</td></tr><tr><td>Sample equivalent analyzed in PCR (μL)</td><td>66,6</td><td>32</td><td>20</td></tr><tr><td>Analysis method</td><td>Melting curve analysis<xref rid="tf0010" ref-type="table-fn">b</xref></td><td>Taqman hydrolysis</td><td>Taqman hydrolysis</td></tr><tr><td>Internal extraction and PCR control</td><td>ARIES-specific, in cassette</td><td>Lab-developed PDV, 10 μL, pipetted manually (+ SPC<xref rid="tf0015" ref-type="table-fn">c</xref>)</td><td>Lab-developed PDV, 10 μL, pipetted automatically</td></tr><tr><td>Primers</td><td><italic>MultiCode</italic> converted, pipetted manually on top of mastermix in snap-on tube, 0.4 μM each</td><td>Unmodified lab-developed, mixed with mastermix, 0.5 μM each</td><td>Unmodified lab-developed, mixed with mastermix, 0.5 μM each</td></tr><tr><td>Probes</td><td>Not applicable</td><td>Unmodified lab-developed, mixed with mastermix, 0.2 μM each</td><td>Unmodified lab-developed, mixed with mastermix, 0.2 μM each</td></tr><tr><td>Mastermix</td><td><italic>ARIES MultiCode Ready Mix</italic>, lyophilized, present in snap-on tube</td><td>1× Taqman Fast Virus 1-Step, 12.5 μL, pipetted manually in snap-in tube</td><td>1× Taqman Fast Virus 1-Step, 15 μL, pipetted automatically</td></tr><tr><td>PCR optimization</td><td>- Generic ARIES PCR<break></break>- MultiCode primer conversion<break></break>- Primer concentrations</td><td>Slightly modified lab-developed PCR with adjusted annealing and extension times</td><td>Identical to lab-developed PCR</td></tr></tbody></table><table-wrap-foot><fn><p>PDV = Phocine Distemper Virus; SPC = Specimen Processing Control; TNA = Total nucleic acid.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0005"><label>a</label><p id="np0005">InGenius extraction kits for 1000-μL sample volumes are under development at the time of writing.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0010"><label>b</label><p id="np0010">ARIES Exo + Ready Mix supporting TaqMan probes is under development at the time of writing.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0015"><label>c</label><p id="np0015">The <italic>Sample Buffer Tube</italic> of the BD MAX extraction kit also contained a <italic>Specimen Processing Control</italic> (SPC), which can be used as an internal control but was not utilized in our study.</p></fn></table-wrap-foot></table-wrap></p><p id="p0050">Luminex ARIES uses no probes but specific <italic>MultiCode</italic> primers (<xref rid="bb0040" ref-type="bibr">Johnson et al., 2004</xref>, <xref rid="bb0055" ref-type="bibr">Sherrill et al., 2004</xref>). Luminex provided MultiCode primers for the MERS-CoV <italic>upE</italic> and <italic>N</italic> targets (no alterations to our original sequence) together with primers for the ARIES-specific internal control. Primer concentrations of 0.2 μM were recommended by Luminex, but in our experience, 0.4 μM resulted in an improved balance between weak positive signals and aspecific amplification products. Therefore, 0.4 μM was used in all subsequent experiments. The general ARIES temperature profile yielded satisfactory results: 7 min 50 °C and 2 min 95 °C followed by 45 cycles of 5 s 95 °C and 7 s 58 °C. Afterwards, melting curve analysis was performed from 60 °C to 95 °C. On the BD MAX and InGenius, unmodified primers/probes with the Fast Virus 1-Step Master Mix and lab-developed PCR temperature profile yielded satisfactory results. Concentrations of reagents remained unchanged. As the BD MAX required sufficient time for fluorometric analysis of all 24 reaction chambers in the PCR cartridge, the annealing/extension time was adjusted from 30 s to the maximum of 24.9 s.</p></sec><sec id="s0035"><label>3.2</label><title>MERS-CoV assay validation</title><p id="p0055">Results of the validation experiments in comparison to the LDT are displayed in <xref rid="t0010" ref-type="table">Table 2</xref>. No discordant or false-positive results were noted after analysis of 32 EQC samples. There was no cross-contamination. The InGenius obtained the highest detection rate by yielding positive results for 5/5 dilutions for <italic>upE</italic> and <italic>N</italic>. Goals for linearity and analysis efficiency were reached with both targets on all 3 systems.<table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>MERS-CoV LDT validation.</p></caption><alt-text id="al0015">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th></th><th>QuantStudio Dx</th><th>ARIES</th><th>BD MAX</th><th>InGenius</th></tr></thead><tbody><tr><td>Accuracy<xref rid="tf0020" ref-type="table-fn">a</xref></td><td>No discordance</td><td>No discordance</td><td>No discordance</td><td>No discordance</td></tr><tr><td>Specificity<xref rid="tf0020" ref-type="table-fn">a</xref></td><td>No false positives</td><td>No false positives</td><td>No false positives</td><td>No false positives</td></tr><tr><td>Cross-reaction<xref rid="tf0020" ref-type="table-fn">a</xref></td><td>None</td><td>None</td><td>None</td><td>None</td></tr><tr><td>Cross-contamination<xref rid="tf0025" ref-type="table-fn">b</xref></td><td>None</td><td>None</td><td>None</td><td>None</td></tr><tr><td>MERS-CoV <italic>UpE</italic>:<break></break>Detection rate<break></break>/ Linearity<xref rid="tf0035" ref-type="table-fn">d</xref></td><td>Detected: 5/5 dilutions<break></break>Ct range<xref rid="tf0030" ref-type="table-fn">c</xref>: 23.7–35.3<break></break><italic>R</italic><sup>2</sup>: 0.988<break></break>118.3% efficiency</td><td>Detected: 3/5 dilutions<break></break>Ct range<xref rid="tf0030" ref-type="table-fn">c</xref>: 30.0–37.1<break></break><italic>R</italic><sup>2</sup> = 1.000<break></break>91.2% efficiency</td><td>Detected: 4/5 dilutions<break></break>Ct range<xref rid="tf0030" ref-type="table-fn">c</xref>: 23.4–32.7<break></break><italic>R</italic><sup>2</sup>: 0.969<break></break>116% efficiency</td><td>Detected: 5/5 dilutions<break></break>Ct range<xref rid="tf0030" ref-type="table-fn">c</xref>: 23.5–37.6<break></break><italic>R</italic><sup>2</sup>: 0.996<break></break>92.7% efficiency</td></tr><tr><td>MERS-CoV <italic>N</italic>:<break></break>Detection rate<break></break>/ Linearity<xref rid="tf0035" ref-type="table-fn">d</xref></td><td>Detected: 5/5 dilutions<break></break>Ct range<xref rid="tf0030" ref-type="table-fn">c</xref>: 24.2–36.2<break></break><italic>R</italic><sup>2</sup>: 0.967<break></break>105.4% efficiency</td><td>Detected: 4/5 dilutions<break></break>Ct range<xref rid="tf0030" ref-type="table-fn">c</xref>: 29.1–39.5<break></break><italic>R</italic><sup>2</sup> = 0.998<break></break>92.3% efficiency</td><td>Detected: 4/5 dilutions<break></break>Ct range<xref rid="tf0030" ref-type="table-fn">c</xref>: 24.4–32.9<break></break><italic>R</italic><sup>2</sup>: 0.981<break></break>131% efficiency</td><td>Detected: 5/5 dilutions<break></break>Ct range<xref rid="tf0030" ref-type="table-fn">c</xref>: 22.9–35.2<break></break><italic>R</italic><sup>2</sup>: 0.999<break></break>109.7% efficiency</td></tr></tbody></table><table-wrap-foot><fn id="tf0020"><label>a</label><p id="np0020">Analysis of 32 EQC samples: 16 MERS-CoV positive, 8 OC43-CoV positive, 1 NL63-CoV positive, and 7 CoV negative.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0025"><label>b</label><p id="np0025">Determined by analysis of a negative sample adjacent to a positive sample.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0030"><label>c</label><p id="np0030">MultiCode Ct values are typically higher than TaqMan Ct values (<xref rid="bb0060" ref-type="bibr">Voermans et al., 2016</xref>).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0035"><label>d</label><p id="np0035">Determined on a 10-fold dilution series (5 dilutions) of a strong positive MERS-CoV EQC sample (Ct value Quantstudio ≈ 22).</p></fn></table-wrap-foot></table-wrap></p><p id="p0060">The ARIES system had a lower detection rate on the dilution series and yielded positive results for 3/5 and 4/5 dilutions for <italic>upE</italic> and <italic>N</italic>, respectively (<xref rid="t0010" ref-type="table">Table 2</xref>). Some of the MERS-CoV–negative EQC samples also resulted in amplification plots with high Ct values. These amplifications proved aspecific based on the melting curve and Tm interval. As they fell outside of the prespecified Tm intervals for <italic>upE</italic> and <italic>N,</italic> these plots were called negative by the automatic software interpretation.</p></sec><sec id="s0040"><label>3.3</label><title>Hands-on system evaluation</title><p id="p0065">For all 3 devices, 1-day on-site training proved to be enough to cover all major aspects of using system-specific assays (<xref rid="t0015" ref-type="table">Table 3</xref>). The flow of sample preparation, device loading, TNA extraction, PCR, and clean-up are displayed in <xref rid="f0005" ref-type="fig">Fig. 1</xref>.<table-wrap position="float" id="t0015"><label>Table 3</label><caption><p>Hands-on system evaluation.</p></caption><alt-text id="al0020">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th></th><th>ARIES</th><th>BD MAX</th><th>InGenius</th></tr></thead><tbody><tr><td>Required on-site training</td><td>1 day</td><td>1 day</td><td>1 day</td></tr><tr><td>Possibility to load primary samples</td><td>No, manual pipetting required</td><td>No, manual pipetting required</td><td>Yes</td></tr><tr><td>Storage of TNA extract</td><td>Not available</td><td>Not available</td><td>Available</td></tr><tr><td>Ease of use</td><td>Very easy</td><td>Easy</td><td>Easy/moderate</td></tr><tr><td>Most challenging step</td><td>Manual pipetting of primers</td><td>Manual pipetting of mastermix</td><td>Loading of disposables</td></tr><tr><td>Total hands-on time for 4 samples</td><td>6 min 5 s</td><td>12 min 25 s</td><td>12 min 0 s</td></tr><tr><td>- Sample preparation</td><td>4 min 25 s</td><td>4 min 35 s</td><td>1 min 20 s</td></tr><tr><td>- Device loading</td><td>1 min 10 s</td><td>5 min 40 s</td><td>6 min 50 s</td></tr><tr><td>- Device clean-up</td><td>0 min 30 s</td><td>2 min 10 s</td><td>3 min 50 s</td></tr><tr><td>On-board extraction and PCR time</td><td>1 h 54 min</td><td>1 h 22 min</td><td>2 h 12 min</td></tr><tr><td>Total analysis time</td><td>2 h 0 min 5 s</td><td>1 h 34 min 25 s</td><td>2 h 24 min 0 s</td></tr><tr><td>Reagent cost per sample<xref rid="tf0040" ref-type="table-fn">a</xref></td><td>Contact company</td><td>25.7 €</td><td>12.1 €</td></tr><tr><td>Maximum throughput in a 1-day shift<break></break>(7.5 h)</td><td>- 2 × 6 samples/run<break></break>- ± 2 h/run<break></break>- 36 samples in 3 runs</td><td>- 2 × 12 samples/run<break></break>- ± 1.5 h/run<break></break>- 120 samples in 5 runs</td><td>- 12 samples/run<break></break>- ± 2.5 h/run<break></break>- 36 samples in 3 runs</td></tr><tr><td>Different assays in the same run</td><td>Yes, same PCR profile</td><td>Yes, same extraction kit</td><td>Yes, same extract elution volume</td></tr><tr><td>Number of optical channels for multiplexing</td><td>5 optical channels + melting curve</td><td>5 optical channels + melting curve</td><td>6 optical channels + melting curve</td></tr><tr><td>Software package and location</td><td>SYNCT: separate PC and device</td><td>BD MAX: PC next to device</td><td>InGenius: device</td></tr><tr><td>Automatic result interpretation</td><td>Programmable interpretation.<break></break>Ct value limits and Tm intervals.</td><td>Programmable interpretation.<break></break>Ct value limits.</td><td>Programmable interpretation.<break></break>Ct value limits.</td></tr><tr><td>Onboard reagent traceability</td><td>Extraction cassette</td><td>Sample Buffer Tube<break></break>Extraction cassette</td><td>Extraction cassette<break></break>User-defined reagents</td></tr><tr><td>LIS communication<xref rid="tf0045" ref-type="table-fn">b</xref></td><td>2-way connection</td><td>2-way connection</td><td>2-way connection</td></tr></tbody></table><table-wrap-foot><fn id="tf0040"><label>a</label><p id="np0040">If available, based on the list price (VAT excluded) at the time of writing.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0045"><label>b</label><p id="np0045">Was not evaluated during this study.</p></fn></table-wrap-foot></table-wrap><fig id="f0005"><label>Fig. 1</label><caption><p>Graphical representation of the sample preparation, device loading, TNA extraction, PCR, and clean-up for the BD MAX, ELITe InGenius, and Luminex ARIES.</p><p><italic>Copyright statement:</italic><xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>contains several images derived from device product manuals. Permission was obtained from BD, ELITech, and Luminex to include these images in our manuscript.</italic></p></caption><alt-text id="al0005">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"></graphic></fig></p><p id="p0070">On the ARIES, the <italic>MultiCode</italic> primers are pipetted manually into conical tubes containing lyophilized <italic>MultiCode Ready Mix</italic>. Each tube is then snapped into an analysis cassette. After pipetting of the primary sample, the cassette is placed into a magazine and loaded onto the device. The sample is immediately subjected to extraction, RT-PCR, and melting curve analysis. Clean-up consists of removing the cassettes from the device.</p><p id="p0075">The BD MAX uses <italic>Sample Buffer tubes</italic> containing 750 μL lysis buffer in which primary sample and IC are pipetted manually. After barcode scanning, tubes are placed into a rack containing 1 <italic>Extraction Reagent Strip</italic> per sample. The PCR mix (= primers, probes, and mastermix) is pipetted manually into a conical snap-in tube inserted into an <italic>Extraction Reagent Strip</italic>. The rack is then placed in the device, and after startup, the BD MAX automatically pipets the lysed sample into the <italic>Extraction Reagent Strip</italic> for TNA extraction. The TNA extract is subsequently added to the PCR mix and transferred to the PCR card. RT-PCR is performed in dedicated PCR cards (24 samples/card) with a built-in microfluidics system. Clean-up consists of removing the tubes and strips from the rack and, at the end of the day, cleaning up the interior surface of the device.</p><p id="p0080">The InGenius can accommodate primary samples pipetted into sample tubes (= extraction and PCR mode) or TNA extracts pipetted into cryovials (= PCR only mode). The InGenius is the only system where the TNA eluate can be stored and used for multiple PCRs in subsequent runs (<xref rid="t0015" ref-type="table">Table 3</xref>). The device uses disposables (sample tubes, extract cryovials, extraction strips, PCR cassettes, filter tips) that must be loaded onto the device before analysis. IC and PCR mix (= primers, probes, and mastermix) are placed into a cooled reagent block. After loading, the system starts the extraction (if needed) and PCR. Clean-up consists of removing all disposables, storing remaining IC and PCR mix, storing remaining TNA extract (if needed), and cleaning of interior surfaces.</p><p id="p0085">ARIES was classified as user-friendliest due to its analysis cassette, which required the least hands-on time and manipulation (<xref rid="t0015" ref-type="table">Table 3</xref>). The technicians judged that the manual pipetting steps on the ARIES and BD MAX were the most error-prone. With InGenius, although the system guides the user through reagent and consumable loading, we noticed that it required some training and handling experience to avoid system crashes (e.g., by misalignment of disposables).</p><p id="p0090">ARIES required the least hands-on time. The BD MAX had the shortest analysis time and, in combination with its capability of analyzing 2 × 12 samples in 1 run, the highest throughput in a 1-day shift: 120 samples in 5 runs (<xref rid="t0015" ref-type="table">Table 3</xref>). Different assays can be loaded and analyzed in the same run on all systems if specific conditions are met (<xref rid="t0015" ref-type="table">Table 3</xref>). On the BD MAX and InGenius systems, PCR settings can differ between lanes as the 24 chambers in the BD MAX PCR card and 12 InGenius thermocyclers are individually controlled. Besides the ability to run different PCR assays in 1 run, the instrument “down-time” between analyses is important for urgent sample testing. For the InGenius system, this “down-time” equals the onboard extraction and PCR time (<xref rid="t0015" ref-type="table">Table 3</xref>). For BD MAX, it is limited to the extraction time as new samples can be loaded during PCR. However, the 2 independent extraction trays on the BD MAX system cannot be accessed if extraction is already ongoing in 1 of them. The ARIES system has 2 independent loading trays; if 1 module is running, the other can be used without restrictions.</p><p id="p0095">Information about the supplied software packages is displayed in <xref rid="t0015" ref-type="table">Table 3</xref>. On ARIES, an <italic>open mode</italic> PCR assay must be set up from the SYNCT software on a remote desktop after which the protocol is transferred to the instrument using USB (only needs to be done once). On the InGenius, the supplier must create a new <italic>open mode</italic> PCR protocol, define the assay name, and register PCR reagent volumes on the device. Afterwards, the user can modify all protocol settings. ARIES and BD MAX software allowed modification of all protocol settings without any supplier input. Lot numbers of the system-specific reagents are registered in all software packages (<xref rid="t0015" ref-type="table">Table 3</xref>). On the InGenius, the user can also add lab-developed PCR mix and IC lot numbers to the registry. Although this was not evaluated in our study, all devices can be programmed for automatic interpretation of PCR results using software models and Ct value limits (<xref rid="t0015" ref-type="table">Table 3</xref>). ARIES also accounts for dye/target Tm intervals. Determination of specific Tm intervals in the SYNCT software required us to test a number of additional positive/negative samples.</p></sec></sec><sec id="s0045"><label>4</label><title>Discussion</title><p id="p0100">The ability to rapidly detect or exclude MERS-CoV infections in clinical specimens is important for diagnosis confirmation or termination of isolation measures, respectively (<xref rid="bb0005" ref-type="bibr">Azhar et al., 2014</xref>, <xref rid="bb0025" ref-type="bibr">Corman et al., 2012</xref>, <xref rid="bb0035" ref-type="bibr">de Groot et al., 2013</xref>, <xref rid="bb0050" ref-type="bibr">Lu et al., 2014</xref>, <xref rid="bb0015" ref-type="bibr">van Boheemen et al., 2012</xref>; <xref rid="bb0065" ref-type="bibr">World Health Organization (WHO), 2015</xref>; <xref rid="bb0070" ref-type="bibr">Zaki et al., 2012</xref>). Automated S2R systems provide time and labor savings while delivering simpler workflows through elimination of separate nucleic acid extraction and hands-on steps (<xref rid="bb0010" ref-type="bibr">Beal et al., 2016</xref>). In this study, we migrated our MERS-CoV LDT to 3 <italic>open mode</italic> S2R systems and compared their system properties.</p><p id="p0105">As the Luminex ARIES works through melting curve analysis and Tm intervals, no probes were needed (<xref rid="bb0040" ref-type="bibr">Johnson et al., 2004</xref>, <xref rid="bb0055" ref-type="bibr">Sherrill et al., 2004</xref>). This means that primers might have to be redesigned to exclude off-target amplicons with the same Tm. Our MERS-CoV primers only required addition of a fluorescent-labeled isoC base at the 5′ end of the forward primers for conversion to the <italic>MultiCode</italic> format. As our PDV IC would have required an extra pipetting step and the development of an additional <italic>MultiCode</italic> primer, we decided to use the built-in RNA IC of the ARIES cassettes. It remained unclear whether the lower detection rate obtained with ARIES was due to <italic>MultiCode</italic> primer conversion, melting curve analysis, or limited optimization runs. It is however important to realize that due to differences in technology, MultiCode Ct values are typically higher than TaqMan Ct values (<xref rid="bb0060" ref-type="bibr">Voermans et al., 2016</xref>). Of interest, Luminex reported the release of a new ARIES mastermix and software update in the coming months to also utilize fluorescent labeled TaqMan probes (personal communication).</p><p id="p0110">Device properties hugely influence the selection of a S2R device. First, available CE/IVD and company-developed tests are an important factor to consider. Second, the instrument “down-time” during analysis differs between devices and is important for urgent sample testing. Third, the ability to analyze several targets on the same sample is different for each system. The InGenius system has the advantage that a single extract (providing there is enough extract volume) can be used in 12 separate multiplex reactions (up to 6 optical channels + melting curve) in 1 run. For BD MAX, this is limited to 2 separate multiplex reactions (up to 5 optical channels + melting curve) and, for ARIES, to 1 multiplex reaction (5 optical channels + melting curve). Fourth, system-specific advantages need to be taken into account. InGenius is the only system where the remaining TNA extract can be recovered for storage or further analysis. InGenius is also the only system where the PCR volume and the added TNA volume can be increased to improve sensitivity. In comparison, BD MAX has the highest throughput and Luminex ARIES excels in ease of use. Finally, differences exist in the availability of quantitative assays. While this was not further evaluated during our study, InGenius allows definition of standard curve options for single tests/fluorescent dyes and sample type dependent conversion factors. A standard curve can also be defined on a single test/fluorescent dye on the BD MAX. Quantitative assays have only been developed in research settings for ARIES. At the time of writing, Luminex is developing a SYNCT software update for incorporating standard curves for quantitative analysis (personal communication).</p><p id="p0115">Although our MERS-CoV PCR assay proved both sensitive and specific on all devices, there were several limitations to the study. First, as no MERS-CoV patients were diagnosed in our center, all data were derived from EQC samples which may not be representative for clinical samples during natural infection. EQC samples were not subjected to the same collection, handling, and storage conditions as clinical samples. In addition, only 16 MERS-CoV–positive, 8 OC43-CoV–positive, 1 NL63-CoV–positive and 7 CoV-negative EQC samples were tested, which limit statistical analysis and interpretation of the cross-reaction experiments. Nevertheless, the assays on the 3 systems use the same primers/probe sets and master mix (excluding Luminex ARIES) as our lab-developed PCR on QuantStudio Dx (<xref rid="bb0020" ref-type="bibr">Clancy et al., 2008</xref>, <xref rid="bb0025" ref-type="bibr">Corman et al., 2012</xref>, <xref rid="bb0050" ref-type="bibr">Lu et al., 2014</xref>). The specificity of this LDT was evaluated using high-titer cell cultures positive for hCOV 229E, NL63, OC43, and SARS. Clinical samples positive for other respiratory viruses, including hCoV 229E, NL63, OC43, and HKU-1, were all negative. Second, assay validation experiments were only performed once due to limited reagents and limited availability of the instruments to our laboratory. Therefore, statistically significant differences could not be determined. Especially the difference in detection rate needs to be interpreted with caution as sample composition could influence the extraction efficiency of each device. The hands-on time was measured only once by 1 operator. While this gives an overall indication on the hand-on time required for each device, our analysis does not provide insight in the real-life hands-on time (e.g., different operators, trained versus untrained personnel, day-to-day variability). Third, intra- and interrun reproducibility was not determined in our study due to limited reagents.</p><p id="p0120">In conclusion, while each device had distinguishing system properties with associated advantages/disadvantages, migration of a MERS-CoV LDT to 3 S2R systems was comparable in terms of assay development and validation.</p></sec><sec id="s0050"><title>Author contributions</title><p id="p0125">GF and KB drafted the manuscript and conducted experiments. All authors participated in the conception and design of the study. MVR, VS, SD, and KL supervised the routine molecular diagnostics workflow of MERS-CoV samples. Each author has critically revised the final version of the manuscript and has read and approved the final manuscript.</p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name><surname>Azhar</surname><given-names>E.I.</given-names></name><name><surname>El-Kafrawy</surname><given-names>S.A.</given-names></name><name><surname>Farraj</surname><given-names>S.A.</given-names></name><name><surname>Hassan</surname><given-names>A.M.</given-names></name><name><surname>Al-Saeed</surname><given-names>M.S.</given-names></name><name><surname>Hashem</surname><given-names>A.M.</given-names></name></person-group><article-title>Evidence for camel-to-human transmission of MERS coronavirus</article-title><source>N Engl J Med</source><volume>370</volume><year>2014</year><fpage>2499</fpage><lpage>2505</lpage><pub-id pub-id-type="pmid">24896817</pub-id></element-citation></ref><ref id="bb0010"><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Beal</surname><given-names>S.G.</given-names></name><name><surname>Assarzadegan</surname><given-names>N.</given-names></name><name><surname>Rand</surname><given-names>K.H.</given-names></name></person-group><article-title>Sample-to-result molecular infectious disease assays: clinical implications, limitations and potential</article-title><source>Expert Rev Mol Diagn</source><volume>16</volume><year>2016</year><fpage>323</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">26689497</pub-id></element-citation></ref><ref id="bb0015"><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>van Boheemen</surname><given-names>S.</given-names></name><name><surname>de Graag</surname><given-names>M.</given-names></name><name><surname>Lauber</surname><given-names>C.</given-names></name><name><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Zaki</surname><given-names>A.M.</given-names></name></person-group><article-title>Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans</article-title><source>MBio</source><volume>3</volume><year>2012</year></element-citation></ref><ref id="bb0020"><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Clancy</surname><given-names>A.</given-names></name><name><surname>Crowley</surname><given-names>B.</given-names></name><name><surname>Niesters</surname><given-names>H.</given-names></name><name><surname>Herra</surname><given-names>C.</given-names></name></person-group><article-title>The development of a qualitative real-time RT-PCR assay for the detection of hepatitis C virus</article-title><source>Eur J Clin Microbiol Infect Dis</source><volume>27</volume><year>2008</year><fpage>1177</fpage><lpage>1182</lpage><pub-id pub-id-type="pmid">18551325</pub-id></element-citation></ref><ref id="bb0025"><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Eckerle</surname><given-names>I.</given-names></name><name><surname>Bleicker</surname><given-names>T.</given-names></name><name><surname>Zaki</surname><given-names>A.</given-names></name><name><surname>Landt</surname><given-names>O.</given-names></name><name><surname>Eschbach-Bludau</surname><given-names>M.</given-names></name></person-group><article-title>Detection of an novel human coronavirus by real-time reverse-transcription polymerase chain reaction</article-title><source>Euro Surveill</source><volume>17</volume><year>2012</year></element-citation></ref><ref id="bb0030"><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name><surname>Felder</surname><given-names>R.A.</given-names></name><name><surname>Jackson</surname><given-names>K.D.</given-names></name><name><surname>Walter</surname><given-names>A.M.</given-names></name></person-group><article-title>Process evaluation of an open architecture real-time molecular laboratory platform</article-title><source>J Lab Autom</source><volume>19</volume><year>2014</year><fpage>468</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">24811476</pub-id></element-citation></ref><ref id="bb0035"><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name><surname>de Groot</surname><given-names>R.J.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name><name><surname>Brown</surname><given-names>C.S.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Enjuanes</surname><given-names>L.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group</article-title><source>J Virol</source><volume>87</volume><year>2013</year><fpage>7790</fpage><lpage>7792</lpage><pub-id pub-id-type="pmid">23678167</pub-id></element-citation></ref><ref id="bb0040"><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>S.C.</given-names></name><name><surname>Sherrill</surname><given-names>C.B.</given-names></name><name><surname>Marshall</surname><given-names>D.J.</given-names></name><name><surname>Moser</surname><given-names>M.J.</given-names></name><name><surname>Prudent</surname><given-names>J.R.</given-names></name></person-group><article-title>A third base pair for the polymerase chain reaction: inserting isoC and isoG</article-title><source>Nucleic Acids Res</source><volume>32</volume><year>2004</year><fpage>1937</fpage><lpage>1941</lpage><pub-id pub-id-type="pmid">15051811</pub-id></element-citation></ref><ref id="bb0045"><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Juretschko</surname><given-names>S.</given-names></name><name><surname>Mahony</surname><given-names>J.</given-names></name><name><surname>Buller</surname><given-names>R.S.</given-names></name><name><surname>Manji</surname><given-names>R.</given-names></name><name><surname>Dunbar</surname><given-names>S.</given-names></name><name><surname>Walker</surname><given-names>K.</given-names></name></person-group><article-title>Multicenter clinical evaluation of the Luminex Aries Flu A/B & RSV assay for pediatric and adult respiratory tract specimens</article-title><source>J Clin Microbiol</source><volume>55</volume><year>2017</year><fpage>2431</fpage><lpage>2438</lpage><pub-id pub-id-type="pmid">28539342</pub-id></element-citation></ref><ref id="bb0050"><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Whitaker</surname><given-names>B.</given-names></name><name><surname>Sakthivel</surname><given-names>S.K.</given-names></name><name><surname>Kamili</surname><given-names>S.</given-names></name><name><surname>Rose</surname><given-names>L.E.</given-names></name><name><surname>Lowe</surname><given-names>L.</given-names></name></person-group><article-title>Real-time reverse transcription-PCR assay panel for Middle East respiratory syndrome coronavirus</article-title><source>J Clin Microbiol</source><volume>52</volume><year>2014</year><fpage>67</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">24153118</pub-id></element-citation></ref><ref id="bb0055"><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name><surname>Sherrill</surname><given-names>C.B.</given-names></name><name><surname>Marshall</surname><given-names>D.J.</given-names></name><name><surname>Moser</surname><given-names>M.J.</given-names></name><name><surname>Larsen</surname><given-names>C.A.</given-names></name><name><surname>Daude-Snow</surname><given-names>L.</given-names></name><name><surname>Jurczyk</surname><given-names>S.</given-names></name></person-group><article-title>Nucleic acid analysis using an expanded genetic alphabet to quench fluorescence</article-title><source>J Am Chem Soc</source><volume>126</volume><year>2004</year><fpage>4550</fpage><lpage>4556</lpage><pub-id pub-id-type="pmid">15070373</pub-id></element-citation></ref><ref id="bb0060"><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name><surname>Voermans</surname><given-names>J.J.</given-names></name><name><surname>Seven-Deniz</surname><given-names>S.</given-names></name><name><surname>Fraaij</surname><given-names>P.L.</given-names></name><name><surname>van der Eijk</surname><given-names>A.A.</given-names></name><name><surname>Koopmans</surname><given-names>M.P.</given-names></name><name><surname>Pas</surname><given-names>S.D.</given-names></name></person-group><article-title>Performance evaluation of a rapid molecular diagnostic, MultiCode based, sample-to-answer assay for the simultaneous detection of influenza A, B and respiratory syncytial viruses</article-title><source>J Clin Virol</source><volume>85</volume><year>2016</year><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">27835760</pub-id></element-citation></ref><ref id="bb0065"><element-citation publication-type="other" id="rf0065"><person-group person-group-type="author"><name><surname>World Health Organization (WHO)</surname></name></person-group><article-title>Laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV) — interim guidance (updated)</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/disease/coronavirus_infections/mers-laboratory-testing/en/" id="ir0005">https://www.who.int/csr/disease/coronavirus_infections/mers-laboratory-testing/en/</ext-link><year>2015</year></element-citation></ref><ref id="bb0070"><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>A.M.</given-names></name><name><surname>van Boheemen</surname><given-names>S.</given-names></name><name><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name></person-group><article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title><source>N Engl J Med</source><volume>367</volume><year>2012</year><fpage>1814</fpage><lpage>1820</lpage><pub-id pub-id-type="pmid">23075143</pub-id></element-citation></ref></ref-list><ack id="ac0005"><sec id="s0055"><title>Acknowledgment</title><p id="p0130">We thank BD, ELITechGroup, and Luminex for providing use of the instruments and the necessary training. All instrument-specific consumables and reagents for the BD MAX and InGenius were supplied free of charge by BD and ELITechGroup, respectively. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></sec><sec id="s0060"><title>Disclosure of potential conflicts of interest</title><sec id="s0065"><title>Funding</title><p id="p0135">All instrument-specific consumables and reagents for the BD MAX and InGenius were supplied free of charge by BD and ELITechGroup, respectively. This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.</p></sec><sec id="s0070"><title>Conflicts of interest</title><p id="p0140">The authors declare that they have no conflict of interest.</p></sec><sec id="s0075"><title>Compliance with ethical standards</title><p id="p0145">Research involving human participants and/or animals: not applicable.</p><p id="p0150">Informed consent: not applicable.</p></sec></sec></ack></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C05 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000C05 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7127711
|texte= Migrating a lab-developed MERS-CoV real-time PCR to 3 “Sample to Result” systems: experiences on optimization and validation
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:30929995" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |